Manufacturer
Pfizer Manufacturing Deutschland GmbH.
Contents
Crizotinib
Indication
Advanced non-small cell lung cancer (NSCLC) whose tumors are anaphylastic lymphoma kinase (ALK) +ve & metastatic NSCLC whose tumors are ROS1 +ve.
Instruction
May be taken with or without food: Swallow whole, do not crush/chew/open cap.
Drug interaction
Increased plasma conc w/ strong CYP3A inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin & voriconazole) & grapefruit or grapefruit juice. Moderate CYP3A inhibitors. Decreased plasma conc w/ strong CYP3A inducers (eg, carbamazepine, phenobarb, phenytoin, rifabutin, rifampin & St. John's wort). Altered plasma conc of CYP3A substrates w/ narrow therapeutic indices (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus & tacrolimus).
Malaysia
